Found: 102
Select item for more details and to access through your institution.
Current Controversies in the Management of Hodgkin's Lymphoma.
- Published in:
- 2007
- By:
- Publication type:
- Letter
Eastern Cooperative Oncology Group 4402: Rituximab Extended Schedule or Retreatment Trial (RESORT).
- Published in:
- Clinical Lymphoma & Myeloma, 2006, v. 6, n. 5, p. 423, doi. 10.3816/clm.2006.n.024
- By:
- Publication type:
- Article
Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies.
- Published in:
- British Journal of Haematology, 2017, v. 179, n. 3, p. 430, doi. 10.1111/bjh.14870
- By:
- Publication type:
- Article
Outcomes of MYC-associated lymphomas after R- CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704.
- Published in:
- British Journal of Haematology, 2016, v. 174, n. 5, p. 686, doi. 10.1111/bjh.14100
- By:
- Publication type:
- Article
Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402.
- Published in:
- British Journal of Haematology, 2016, v. 173, n. 6, p. 867, doi. 10.1111/bjh.14007
- By:
- Publication type:
- Article
Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: A Wisconsin Oncology Network Study.
- Published in:
- British Journal of Haematology, 2016, v. 173, n. 2, p. 283, doi. 10.1111/bjh.13957
- By:
- Publication type:
- Article
Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era.
- Published in:
- British Journal of Haematology, 2015, v. 171, n. 4, p. 530, doi. 10.1111/bjh.13634
- By:
- Publication type:
- Article
A phase II trial of RCHOP followed by radioimmunotherapy for early stage (stages I/ II) diffuse large B-cell non-Hodgkin lymphoma: ECOG3402.
- Published in:
- British Journal of Haematology, 2015, v. 170, n. 5, p. 679, doi. 10.1111/bjh.13493
- By:
- Publication type:
- Article
Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20<sup>+</sup> lymphoid malignancies.
- Published in:
- British Journal of Haematology, 2015, v. 170, n. 5, p. 669, doi. 10.1111/bjh.13487
- By:
- Publication type:
- Article
Response-adapted therapy for aggressive non-Hodgkin's lymphomas based on early [18F] FDG-PET scanning: ECOG-ACRIN Cancer Research Group study (E3404).
- Published in:
- British Journal of Haematology, 2015, v. 170, n. 1, p. 56, doi. 10.1111/bjh.13389
- By:
- Publication type:
- Article
Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma.
- Published in:
- Molecular Cancer, 2008, v. 7, p. 1, doi. 10.1186/1476-4598-7-40
- By:
- Publication type:
- Article
Checkpoint inhibitor‐based salvage regimens prior to autologous stem cell transplant improve event‐free survival in relapsed/refractory classic Hodgkin lymphoma.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 3, p. 464, doi. 10.1002/ajh.26827
- By:
- Publication type:
- Article
Outcomes of patients with limited‐stage plasmablastic lymphoma: A multi‐institutional retrospective study.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 2, p. 300, doi. 10.1002/ajh.26784
- By:
- Publication type:
- Article
Current Status of Targeted Therapies for Mantle Cell Lymphoma.
- Published in:
- 2011
- By:
- Publication type:
- Journal Article
Current Treatments in Marginal Zone Lymphoma.
- Published in:
- Oncology (08909091), 2022, v. 36, n. 4, p. 206
- By:
- Publication type:
- Article
Recent Advances in Antibody-Drug Conjugates for Lymphoma.
- Published in:
- Oncology (08909091), 2020, v. 34, n. 12, p. 522
- By:
- Publication type:
- Article
Splenic Lymphomas Presenting as Splenomegaly.
- Published in:
- Oncology (08909091), 2015, v. 29, n. 6, p. 427
- By:
- Publication type:
- Article
Nodal Marginal Zone Lymphoma: What Do We Really Know?
- Published in:
- Oncology (08909091), 2012, v. 26, n. 1, p. 108
- By:
- Publication type:
- Article
Evaluation of sulfonamide detoxification pathways in haematologic malignancy patients prior to intermittent trimethoprim-sulfamethoxazole prophylaxis.
- Published in:
- British Journal of Clinical Pharmacology, 2011, v. 71, n. 4, p. 566, doi. 10.1111/j.1365-2125.2010.03889.x
- By:
- Publication type:
- Article
Metabolic Biomarkers Assessed with PET/CT Predict Sex-Specific Longitudinal Outcomes in Patients with Diffuse Large B-Cell Lymphoma.
- Published in:
- Cancers, 2022, v. 14, n. 12, p. 2932, doi. 10.3390/cancers14122932
- By:
- Publication type:
- Article
Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (111 In)/Yttrium 90 (90 Y) Ibritumomab Tiuxetan (Zevalin ®) Theranostic Pair in Patients with Lymphoma at Myeloablative Dose Levels.
- Published in:
- Cancers, 2021, v. 13, n. 11, p. 2828, doi. 10.3390/cancers13112828
- By:
- Publication type:
- Article
With a Little Help From My Friends.
- Published in:
- Clinical Advances in Hematology & Oncology, 2018, v. 16, n. 12, p. 776
- By:
- Publication type:
- Article
Loncastuximab Tesirine in Patients With B-Cell Non-Hodgkin Lymphoma.
- Published in:
- Clinical Advances in Hematology & Oncology, 2018, v. 16, n. 11, p. 732
- By:
- Publication type:
- Article
On RELEVANCE.
- Published in:
- Clinical Advances in Hematology & Oncology, 2018, v. 16, n. 10, p. 634
- By:
- Publication type:
- Article
The Fast-Changing World of CLL.
- Published in:
- Clinical Advances in Hematology & Oncology, 2018, v. 16, n. 6, p. 396
- By:
- Publication type:
- Article
More CRO Fun.
- Published in:
- Clinical Advances in Hematology & Oncology, 2018, v. 16, n. 5, p. 304
- By:
- Publication type:
- Article
Mentoring.
- Published in:
- Clinical Advances in Hematology & Oncology, 2018, v. 16, n. 4, p. 234
- By:
- Publication type:
- Article
Outcomes of Patients With Burkitt Lymphoma Older Than Age 40 Treated With Intensive Chemotherapeutic Regimens.
- Published in:
- Clinical Lymphoma & Myeloma, 2009, v. 9, n. 4, p. 307, doi. 10.3816/CLM.2009.n.060
- By:
- Publication type:
- Article
Thalidomide Maintenance Following High-Dose Melphalan with Autologous Stem Cell Support in Myeloma.
- Published in:
- Clinical Lymphoma & Myeloma, 2008, v. 8, n. 3, p. 153
- By:
- Publication type:
- Article
Dose-Intense and Dose-Dense Regimens in Hodgkin Lymphoma and Aggressive Non-Hodgkin Lymphoma.
- Published in:
- Clinical Lymphoma & Myeloma, 2007, v. 8, p. S42
- By:
- Publication type:
- Article
Clinical outcomes in patients relapsed/refractory after ≥2 prior lines of therapy for follicular lymphoma: a systematic literature review and meta-analysis.
- Published in:
- BMC Cancer, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12885-023-10546-6
- By:
- Publication type:
- Article
Is local review of positron emission tomography scans sufficient in diffuse large B‐cell lymphoma clinical trials? A CALGB 50303 analysis.
- Published in:
- Cancer Medicine, 2023, v. 12, n. 7, p. 8211, doi. 10.1002/cam4.5628
- By:
- Publication type:
- Article
Current and emerging treatment options for mantle cell lymphoma.
- Published in:
- Therapeutic Advances in Hematology, 2017, v. 8, n. 8, p. 223, doi. 10.1177/2040620717719616
- By:
- Publication type:
- Article
Bendamustine Produces Durable Responses With an Acceptable Safety Profile in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2010, v. 10, n. 6, p. 452, doi. 10.3816/CLML.2010.n.079
- By:
- Publication type:
- Article
Rituximab and CHOP Chemotherapy Plus GM-CSF for Previously Untreated Diffuse Large B-Cell Lymphoma in the Elderly: A Wisconsin Oncology Network Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2010, v. 10, n. 5, p. 379, doi. 10.3816/CLML.2010.n.071
- By:
- Publication type:
- Article
Mantle Cell Lymphoma: First-line Therapy in Patients Not Eligible for Stem Cell Transplantation.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Follicular lymphoma: Management options in the era of targeted therapy.
- Published in:
- Current Treatment Options in Oncology, 2005, v. 6, n. 4, p. 297, doi. 10.1007/s11864-005-0034-x
- By:
- Publication type:
- Article
A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma.
- Published in:
- Cancer (0008543X), 2006, v. 107, n. 12, p. 2826, doi. 10.1002/cncr.22342
- By:
- Publication type:
- Article
Immunohistochemical evaluation of MYC expression in mantle cell lymphoma.
- Published in:
- Histopathology, 2013, v. 63, n. 4, p. 499, doi. 10.1111/his.12207
- By:
- Publication type:
- Article
SOHO State of the Art Updates and Next Questions: Tailoring Upfront Therapy in Mantle Cell Lymphoma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 9, p. 633, doi. 10.1016/j.clml.2023.05.003
- By:
- Publication type:
- Article
Bendamustine/Rituximab Plus Cytarabine/Rituximab, With or Without Acalabrutinib, for the Initial Treatment of Transplant-Eligible Mantle Cell Lymphoma Patients: Pooled Data From Two Pilot Studies.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 7, p. 552, doi. 10.1016/j.clml.2023.04.003
- By:
- Publication type:
- Article
Safety and Efficacy of Ruxolitinib in Patients with Myelofibrosis and Low Platelet Counts (50 - 100 x 10<sup>9</sup>/L): Final Analysis of an Open-Label Phase 2 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 5, p. 336, doi. 10.1016/j.clml.2021.10.016
- By:
- Publication type:
- Article
Health-Related Quality of Life, Symptoms, and Tolerability of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 3, p. 158, doi. 10.1016/j.clml.2021.09.001
- By:
- Publication type:
- Article
ABCL-022: LOTIS-2 Follow-Up Analysis: Updated Results from a Phase 2 Study of Loncastuximab Tesirine (Lonca) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S377, doi. 10.1016/S2152-2650(21)01861-9
- By:
- Publication type:
- Article
Poster: ABCL-022: LOTIS-2 Follow-Up Analysis: Updated Results from a Phase 2 Study of Loncastuximab Tesirine (Lonca) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S238, doi. 10.1016/S2152-2650(21)01495-6
- By:
- Publication type:
- Article
Oral Abstract: ABCL-022: LOTIS-2 Follow-Up Analysis: Updated Results from a Phase 2 Study of Loncastuximab Tesirine (Lonca) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S203, doi. 10.1016/S2152-2650(21)01278-7
- By:
- Publication type:
- Article
Tailoring Upfront Therapy in Mantle Cell Lymphoma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S186, doi. 10.1016/S2152-2650(21)01260-X
- By:
- Publication type:
- Article
Can We Exploit the Molecular Heterogeneity of Aggressive B Cell Lymphomas Into Effective New Therapies?
- Published in:
- 2019
- By:
- Publication type:
- Editorial
VcR-CVAD Induction Chemotherapy Followed by Maintenance Rituximab Produces Durable Remissions in Mantle Cell Lymphoma: A Wisconsin Oncology Network Study.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma.
- Published in:
- 2016
- By:
- Publication type:
- journal article